VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                           

 

29th May - New research

CLINICAL TRIAL OF SAFINAMIDE FOR PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Safinamide has both dopaminergic properties (highly selective and reversible inhibition of monoamine oxidase-B) and non-dopaminergic properties (selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release). It is usually added to the use of L-dopa or dopamine agonists. For more information go to Xadago : Xadago

The use of L-dopa is limited by wearing off and dyskinesias. The objective of this study was to investigate the efficacy and safety of safinamide in L-dopa treated patients who had motor fluctuations. If no tolerability issues arose by day 14, the starting dose, 50 mg, was increased to 100 mg. When taking safinamide, the mean change in daily on time without dyskinesia 2.80 hours. However, this was not much different from the effect that a placebo had. The most frequently reported adverse event was dyskinesia (14%], and as a severe event (2%). These results are consistent with previous studies in which the increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. For more news go to Parkinson's Disease News

Reference : JAMA Neurology [2017] 74 (2) : 216-224 (A.H.Schapira, S.H.Fox, R.A.Hauser, J.Jankovic, W.H.Jost, C.Kenney, J.Kulisevsky, R.Pahwa, W.Poewe, R.Anand) Complete abstract


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


 

THE COMPREHENSIVE GUIDE TO PARKINSON'S DISEASE

The Comprehensive Guide to Parkinson's Disease, which is fully referenced, and over 800 pages long, is the most comprehensive book concerning Parkinson's Disease. It includes the history of Parkinson 's Disease, famous people with Parkinson's Disease, the complete biochemisty of Parkinson's Disease,
its cytology and cytological effects, anatomy and anatomical effects, physiology and physiological effects, symptoms of every system in the body, the diagnosis methods (observational, technological, chemical), biochemical causes, all the toxic causes, all the genetic causes, all the pharmacological causes, all the medical disorders that cause Parkinson's Disease symptoms, its treatments (biochemical, pharmacological, surgical, natural, exercise methods, technological methods), including all those treatments that exist and all those treatments presently being developed, Parkinson's Disease organisations, Parkinson's Disease web sites, and books on Parkinson's Disease nursing. CLICK HERE FOR MORE DETAILS

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
©2006-2017  Viartis
 
2017-05-29 22:19:32
 
[email protected]